Biopharmaceutical News and Research

RSS

Access Pharmaceuticals to present two oncology posters at CPR Conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.

18 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

Selenium secures NIH grant to apply patented antimicrobial technology for ear infections

Selenium, Ltd., a biopharmaceutical company focused on unique solutions to meet antimicrobial coating and therapeutic needs, has been awarded a research grant from the National Institute on Deafness and Other Communication Disorders, one of the National Institutes of Health. With the $155,387 NIH grant the company will apply its proprietary antimicrobial technology to researching the inhibition of biofilms on tympanostomy tubes.

18 Nov 2010

Anthera places voluntary hold on A-623 Phase 2b study for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has notified the US Food and Drug Administration (FDA) that the company has placed a voluntary hold on PEARL-SC, the Phase 2b study of A-623 for the treatment of Systemic Lupus Erythematosus (lupus), due to problems found with product vials.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Verastem closes $16 million Series A financing

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.

16 Nov 2010

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, today announced that it was awarded an Innovation Credit of EUR 1.3 million from the Dutch government.

16 Nov 2010

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Dyadic third quarter total revenue decreases to $2.0 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

PAREXEL wins 2010 Scrip Award for 'Clinical Research Team of the Year'

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has won the 2010 Scrip Award for "Clinical Research Team of the Year." The award was presented to PAREXEL at the sixth annual Scrip Awards ceremony, hosted by Scrip Intelligence, a leading news, data, and information service for the global pharmaceutical industry, on November 4, 2010 in London, England.

From Parexel 15 Nov 2010

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme.

14 Nov 2010

Hana Biosciences announces financial results of third quarter 2010

Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.

12 Nov 2010

Soligenix third quarter revenues increase to $861,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010.

12 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.

10 Nov 2010

Appeals court upholds five-year exclusivity period for Shire's VYVANSE

Shire plc, the global specialty biopharmaceutical company, announces that the U.S. Court of Appeals for the District of Columbia Circuit has affirmed the ruling of the U.S. District Court for the District of Columbia and the U.S. Food and Drug Administration to grant five-year New Chemical Entity exclusivity to lisdexamfetamine dimesylate, currently marketed by Shire U.S. Inc. under the name VYVANSE(R).

10 Nov 2010

Biopharmaceutical News and Research

Access Pharmaceuticals to present two oncology posters at CPR Conference

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Selenium secures NIH grant to apply patented antimicrobial technology for ear infections

Anthera places voluntary hold on A-623 Phase 2b study for lupus

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Verastem closes $16 million Series A financing

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Dyadic third quarter total revenue decreases to $2.0 million

PAREXEL wins 2010 Scrip Award for 'Clinical Research Team of the Year'

Sinovac third quarter sales decrease 7% to $9.6 million

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

Hana Biosciences announces financial results of third quarter 2010

Soligenix third quarter revenues increase to $861,000

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Amarin reports $31.4 million cash balance for third quarter 2010

Appeals court upholds five-year exclusivity period for Shire's VYVANSE

Event guide: World ADC San Diego eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News